FDA Ties Brisdelle Approval To Unmet Need For Hormone-Free Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
In an NEJM perspective piece, agency reviewers explain why they believed Noven’s paroxetine for treating hot flashes should come to market despite only “modest” efficacy and an advisory committee’s overwhelming recommendation against approval.